The cost of Wegovy is about to decrease significantly in a populous overseas market.Since pharmaceutical companies rely on the revenue generated from approved medicines, price cuts can put pressure on their fundamentals. That was the dynamic behind Novo Nordisk's (NVO 0.35%) fall on the stock market Monday; news that its Wegovy would cost less in a major market drove the company's shares down by nearly 2%. Chop, chopNovo Nordisk stated only that it was reducing the prices of its highly popular drug in China ...